Update 03.16 PM EST: Adds comments from ResMed The U.S. Food and Drug Administration (FDA) on Thursday classified a product ...

ResMed stands to benefit from Philips’ significant product recall and the launch of its new flagship product, AirSense 11. Market share gains from Philips’ product recall may be limited as ...

ResMed says its masks to remain on market despite FDA classification January 16, 2024 The U.S. Food and Drug Administration (FDA) on Thursday classified the recall of certain respiratory masks ...

While ResMed has maintained its dominance in the sleep apnoea market, analysts said the return of Dutch rival Philips to the US market after a product recall was a potential disruptor.

The renowned medical device company has a market capitalization of $35.10 billion. RMD has an earnings yield of 14.8%, outpacing the industry’s 14.4%. The company’s earnings surpassed estimates in ...

2030 ambition to help more than 500 million people worldwide achieve their full health potential Showcases integration of intelligent products and solutions within the ResMed ecosystem ...

Hello, and welcome to the Q1 Fiscal Year 2025 ResMed Earnings Conference Call. My name is Kevin, and I'll be your operator for today's call. At this time, all participants are in a listen-only mode.

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea ...